A phase IV, blinded, randomized controlled trial to compare the effectiveness of low pressure pneumoperitoneum during laparoscopic donor nephrectomy to optimize the quality-of-recovery during the early postoperative phase

Published: 10-07-2014 Last updated: 20-04-2024

To investigate whether the use of low pressure pneumoperitoneum during laparoscopic donor nephrectomy improves the quality-of-recovery during the early post-operative phase as compared to the use of standard pressure pneumoperitoneum.

Ethical reviewApproved WMOStatusRecruitingHealth condition typeRenal disorders (excl nephropathies)Study typeInterventional

Summary

ID

NL-OMON40838

Source ToetsingOnline

Brief title LEOPARD-2 study

Condition

- Renal disorders (excl nephropathies)
- Renal and urinary tract therapeutic procedures

Synonym

1 - A phase IV, blinded, randomized controlled trial to compare the effectiveness of ... 3-05-2025

donor nephrectomy, kidney donation

Research involving Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Sint Radboud **Source(s) of monetary or material Support:** MSD;Haarlem

Intervention

Keyword: Laparoscopic donornephrectomy, Low pressure pneumoperitoneum, Sugammadex

Outcome measures

Primary outcome

Quality of recovery-40 score on day 1 (overall score)

Secondary outcome

Questionnaires

- Quality of recovery-40 questionnaire
- Return to Work questionnaire

Medication use

- Cumulative morphine use
- Cumulative use of other analgetics
- Cumulative use of anti-emetics

Clinical parameters

- Components of pain assessment
- Evaluation of post-operative complications, graded according to Clavien Dindo
- Post-operative incidence of nausea and/or vomiting
 - 2 A phase IV, blinded, randomized controlled trial to compare the effectiveness of ... 3-05-2025

- Time until reaching discharge criteria*
- Serum creatinine
- Incidence of chronic pain

Intra-operative parameters

• Operation time (min), length of pneuoperitoneum (min), first warm ischemia

time (sec)

- Estimated blood loss (ml)
- Conversion to open donor nephrectomy (incidence)
- Conversion to hand-assisted donor nephrectomy (incidence)
- Intra-operative complications (e.g. bleeding, injury to spleen or liver)
- Urine output during pneumoperitoneum phase
- Cumulative use of rocuronium (mg)
- Cumulative use of sugammadex (mg)
- Surgical rating score

* Discharge criteria are: adequate paincontrole with oral analgetics, absence of nausea/vomiting, passage of flatus or defecation, intake of solid food, patient is mobilized and independent and patient accepts discharge. Discharge criteria will be evaluated daily. If the donor for social reasons wants to stay longer (e.g. long distance and partner or child is still hospitalized) than the *virtual* discharge date is listed. A physician who is independent (ward physician) is responsible for the actual discharge date.

Study description

Background summary

As both patients with end-stage kidney disease and society benefit tremendously from live kidney donation, the safety and well-being of kidney donors are highly important objectives in live kidney donation. Laparoscopic donor nephrectomy has several advantages over open donor nephrectomy, such as less post-operative pain, better quality of life and shorter hospital stay1. Therefore, laparoscopic donor nephrectomy is nowadays the treatment of choice. So far, modifications of the technique of laparoscopic donor nephrectomy, i.e. hand-assisted and/or retroperitoneoscopic approaches, did not show a significant benefit with regard to safety as reflected by the conversion to open and postoperative complication rate2-4. We therefore believe that further research should focus on the optimization of early postoperative recovery. Postoperative recovery is largely determined by the consequences of postoperative pain and its concomitant use of opioids. Since non-steroidal anti-inflammatory drugs are contra-indicated during and after nephrectomy, the management of postoperative pain largely depends on the administration of opioids. Measures to reduce postoperative pain would also reduce the occurrence of postoperative drowsiness, nausea and vomitus, and postoperative bowel dysfunction.

Pain after laparoscopic surgery can be divided into three components: a) superficial wound pain, b) deep intra-abdominal pain and c) referred shoulder pain5. A recent pilot study performed by our group showed that the use of low pressure pneumoperitoneum (7 mmHg) was feasible and significantly reduced deep intra-abdominal and referred pain scores during the first 72 hours after surgery6. Previous studies by others show that low pressure pneumoperitoneum during laparoscopic Nissen fundoplication and laparoscopic cholecystectomy is associated with a reduction of the systemic inflammatory response, less adverse impact on the peritoneal environment, post-operative pain and analgesic consumption7-10.

To facilitate the use of low pressure pneumoperitoneum and to optimize the quality of the surgical conditions (which in theory increases safety of the low pressure pneumoperitoneum), muscle relaxation will be standardized throughout the procedure. In our current practice higher doses of rocuronium are used for laparoscopic donor nephrectomy as compared to standard laparoscopic procedures (e.g. laparoscopic cholecystectomy). To facilitate recovery, suggamadex is used on a regular basis to antagonize the effects of muscle relaxation. Currently, a non-invasive device, the acceleromyograph at the wrist (TOF-watch-SX, MSD), is used to monitor the depth of muscle relaxation aiming at a train-of-four (TOF)

below 2. In our study we use the same device to measure the post tetanic count (PTC), aiming at a count of 1 or 2 which is defined as *deep* muscle relaxation. Instead of additional boluses of rocuronium, a continuous infusion with rocuronium will be used to guarantee a steady PTC of 1 or 2 during the whole procedure. After surgery all patients will receive suggamadex to rapidly antagonize the effects of muscle relaxation. This guarantees that the participants are not exposed to any additional burden related to the use of *deep* muscle relaxation.

Referenties

1. Wilson CH, Sanni A, Rix DA, Soomro NA, Laparoscopic versus open nephrectomy for live kidney donors, Cochrane Database Syst Revi 2011;11:CD006124

2. Kurien A, Rajapurkar S, Sinha L et al, Standard laparoscopic donor nephrectomy versus laparoendoscopic single-site donor nephrectomy: a randomized comparative study, J Endourol 2011;25(3):366-370

3. Dols LFC, Kok NFM, et al, Optimizing left-sided live kidney donation: hand-assisted retroperitoneoscopic as alternative to standard laparoscopic donor nephrectomy, Trans Int 2010;23:358-363

4. Bargman V, Sundaram CP, Bernie J, Goggins W, Randomized trial of laparoscopic donor nephrectomy with and without hand assistance, J Endourol 2006;20(10):717-722

5. Ergün M, Berkers AW, van der Jagt MF et al, Components of pain assessment after laparoscopic

donor nephrectomy, Acta Anaesthesiol Scand, 2013, Epub ahead of print 6. Warlé MC, Berkers AW, Langenhuijsen JF et al, Low-pressure pneumoperitoneum during laparoscopic donor nephrectomy to optimize live donors* comfort, Clin Transplant 2013;27(4):E478-83

7. Schietroma M, Carlei F, Cecilia EM et al, A prospective randomized study of systemic inflammation and immune response after laparoscopic nissen fundoplication performed with standard and low-pressure pneumoperitoneum, Surg Laparosc Endosc Percutan Tech 2013;23(2):189-96

8. Gurusamy KS, Samraj K, Davidson BR, Low pressure versus standard pressure pneumoperitoneum in laparoscopic cholecystectomy, Cochrane Database Syst Rev 2009;2:CD006930

9. Donatsky AM, Bjerrum J, Gögenur I, Surgical techniques to minimize shoulder pain after laparoscopic cholecystectomy. A systematic review. Surg Endosc 2013;27(7):2275-82

10. Matsuzaki S, Jardon K, Maleysson E, D*Arpiany F, Canis M, Botchorishvili R, Impact of intraperitoneal pressure of a CO2 pneumoperitoneum on the surgical peritoneal environment, Human Reprod 2012;27(6):1613-1623

11. Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A, Evaluation of surgical condition during laparoscopic surgery in patients with moderate vs deep neuromuscular block, Br J Anaesth, 2013; epub ahead of print

 Lindekaer AL, Halvor Springborg H, Istre O, Deep neuromuscular blockade leads to a larger intraabdominal volume during laparoscopy, J Vis Exp 2013;76
 Debaene B, Plaub B, Dilly MP, Donati F, Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action, Anesthesiology 2003;98:1042-1048

14. Murphy GS, Brull SJ, Residual neuromuscular block: lessons unlearned. Part 1: definitions, incidence, and adverse physiologic effects of residual neuromuscular block, Anesth Analg, 2010;111:120-8

15. Blobner M, Eriksson L.I., Scholz J, Motsch J, Della Rocca G., Prins M.E.,

Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomized,

controlled trial, Eur. J. Anaesthesiol 2010; 27:874-881

16. Ledowski T, Falke L, Johnston F et al, Retrospective investigation of

postoperative outcome after reversal of residual neuromuscular blockade:

sugammadex, neostigmine or no reversal, Eur J Anaesthesiol 2013 epub ahead of print

17. Suy K, Morias K, Cammu G et al, Effective reversal of moderate rocuroniumor vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent, Anestesiology 2007;106:283-8

18. Carron M, Veronese S, Foletto M, Ori C, Sugammadex allows fast-track bariatric surgery, Obes Surg 2013;23:1553-1563

19. Amao R, Zornow MH, Cowan RM, Cheng DC, Morte JB, Allard MW, Use of sugammadex in patients with a history of pulmonary disease, J Clin Anesth 2012;24:289-97

20. Mirakhur RK, Sugammadex in clinical practice, Anaesthesia 2009; 64;45-54

Study objective

To investigate whether the use of low pressure pneumoperitoneum during laparoscopic donor nephrectomy improves the quality-of-recovery during the early post-operative phase as compared to the use of standard pressure pneumoperitoneum.

Study design

Single-center, single-blind, randomized, controlled clinical trial

Intervention

The patient will be randomized in one the following study groups:

- Standard pressure pneumoperitoneum (12 mmHg)
- Low pressure pneumoperitoneum (6 mmHg)

Study burden and risks

The patient will be asked to fill in some questionnaires:

- Quality of recovery-40: 5x 5 minutes = 25 minutes
- Return to work: 3x 5 minutes = 15 minutes
- Components of pain assessment: 7x 2 minutes = 14 minutes
- Nausea score = 5x 1 minute = 5 minutes

Total estimated 59 minutes

Contacts

Public

Universitair Medisch Centrum Sint Radboud

Geert Grooteplein Zuid 10 Nijmegen 6525GA NL **Scientific** Universitair Medisch Centrum Sint Radboud

Geert Grooteplein Zuid 10 Nijmegen 6525GA NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years) Elderly (65 years and older)

Inclusion criteria

Obtained informed consent Age over 18 years

Exclusion criteria

• insufficient control of the Dutch language to read the patient information and to fill out the questionnaires

7 - A phase IV, blinded, randomized controlled trial to compare the effectiveness of ... 3-05-2025

- chronic use of analgetics or psychotropic drugs
- use of NSAIDs shorter than 5 days before surgery
- known of suspect allergy to rocuronium or sugammadex
- significant liver* or renal** dysfunction
- neuromuscular disease

• pregnant of breastfeeding;*Liver dysfunction is defined as alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) > twice the upper limit (extremely rare in live kidney donors)

** renal dysfunction is defined as serum creatinine twice the normal level and/or glomerular filtration rate < 60 ml/min (extremely rare in live kidney donors)

Study design

Design

Study phase:	4
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Single blinded (masking used)

Primary purpose: Treatment

Recruitment

. . .

NL	
Recruitment status:	Recruiting
Start date (anticipated):	26-08-2014
Enrollment:	64
Туре:	Actual

Ethics review

10-07-2014
First submission
CMO regio Arnhem-Nijmegen (Nijmegen)
03-09-2014

8 - A phase IV, blinded, randomized controlled trial to compare the effectiveness of ... 3-05-2025

Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

 Register
 ID

 CCMO
 NL48056.091.14